Clear sex differences exist in asthma and atopy with a preponderance of boys before puberty. There is a reversal of this sex ratio during puberty with girls having more asthma and atopy throughout the reproductive years. Elucidating the reasons for the switch in the sex ratio should provide fresh insights into asthma and atopy with a real prospect of novel therapies for these troublesome diseases. The challenge is to match the epidemiology and physiology with the accumulating scientific knowledge on gender differences in immune responses. Hormonal changes have been implicated in the reversal of the sex ratio. Testosterone is an immunosuppressant and is likely to be protective, while female sex steroids are proinflammatory and will increase the susceptibility to atopy. Modified so as to be non-virilising/feminising, sex steroids could therefore play a useful part in modulating the immunological and inflammatory processes that underlie asthma and other allergic disorders, complementing the currently used glucocorticoid derived steroids.

**SEX AND DISEASE**

Beyond the obvious male/female divergence of physical characteristics during puberty there are intriguing and potentially informative sex differences in the expression and underlying mechanisms of a range of health problems. These include asthma, arthritis, migraine, depression, diabetes, epilepsy, and neurodevelopment. Sex differences are evident in mortality and morbidity figures, prescribing patterns, and in hospital admissions. These differences may be altered with the onset of puberty. Unravelling these patterns of sickness and health may contribute to understanding the processes that initiate and perpetuate disease, leading to disease prevention and improved therapy.

**REPORTED SEX DIFFERENCES IN ASTHMA AND ALLERGY**

Epidemiological studies, of both incidence and prevalence, have reported a male predominance of asthma and atopic conditions before puberty and a female predominance after puberty. The National Child Development Study in the UK observed a male predominance in the incidence of reported asthma before 16 years of age with a reversal of the sex ratio thereafter. Similar findings have been reported for the prevalence of wheeze and asthma, with higher rates in women through the reproductive years. The influences of gender are also seen for hospital admissions, with more boys admitted before puberty and a gender reversal evident post-puberty. The sex differences in admission rates are of a magnitude that is easily and consistently demonstrable. For example, this pattern is noticeable in the annual admission rate for asthma in all hospitals in Scotland (fig 1). The hospital admission data probably reflect more than predisposition and suggest possible differences in severity. In asthma cases followed prospectively from childhood, severity decreased during adolescence only among males. Cross sectional studies also show that females are more likely to develop late onset and persistent wheeze.

The prevalence of reported hay fever is greater in prepubertal boys, with a change to a female predominance in adolescence. Girls have higher reported eczema prevalence in early childhood; this gender difference becomes more noticeable with time.

**Abbreviations:** BHR, bronchial hyperresponsiveness; SLE, systemic lupus erythematosus
CURRENT AND ALTERNATIVE PERSPECTIVES ON SEX DIFFERENCES IN ASTHMA AND ATOPY

Current explanations include sociocultural influences on diagnostic labelling or sex differences in lung development and function.

Sociocultural factors have been suggested to lead to under-diagnosis of asthma in younger girls. The phenomenon of what has been termed the “Yentl syndrome”, where girls and young women are treated differently by the medical profession despite an equal disease severity to males, has been invoked to explain under-diagnosis of asthma in girls. Gender differences in perception and reporting threshold of symptoms may also influence detection and diagnosis of disease. This explanation remains speculative and does not address the reversal of the sex ratio in the transition from childhood to adulthood.

There is evidence that airway development is different between the sexes, with a relative slow pace of airway development compared with growth of lung volume in males, so called dysnaptic lung growth. In females there is proportionate growth of airways to lung volume and as a consequence greater air flow rates at fixed proportions of total lung capacity. Boys have lower expiratory air flow rates at all comparable lung volumes. As the likelihood of symptoms of airway obstruction will be influenced by baseline values, this places the males at a disadvantage, particularly with viral induced wheeze. This sex difference reverses at puberty with an acceleration of all indices of lung function in males. This sex difference reverses at puberty with an acceleration of all indices of lung function in males. 

Factors other than lung function and growth, and in particular sex related differences in immune response, are at work during puberty, as clearly indicated by the gender switch in the luteal and follicular phase respectively, just at the time when sex steroids are at their highest levels. The reversal of the male/female prevalences of asthma and other atopic conditions at puberty strongly suggests a role for sex hormones. The known influences of the menstrual cycle on asthma support a role for female sex hormones in the changing expression of atopy and asthma during puberty and adolescence. In the 30–50% of women so affected deteriorations can also occur in the premenstrual phase, although exacerbations can also occur in the ovulatory phase. Both BHR and skin reactivity increase during the menstrual cycle, peaking in the luteal and follicular phase respectively, just at the time when sex steroids are at their highest levels.

Although the immunomodulatory properties of sex steroids have been known for many years in the autoimmunity field, this knowledge has seldom been applied to asthma and allergy although there is some evidence of their contribution to relevant underlying mechanisms. Oestrogen enhances, while testosterone inhibits eosinophil release. Testosterone is a powerful inhibitor of histamine. Oestrogen augments while testosterone and tamoxifen, an oestrogen antagonist, inhibit mast cell degranulation.
SEX HORMONES AND AUTOIMMUNITY

To understand the mechanisms underlying gender predispositions and the influences of sex hormones on the expression of autoimmune disease, it is instructive to draw a parallel with their known influence on autoimmunity. Sex differences have been clearly shown in the expression of autoimmune diseases, with females comprising approximately 75% of all cases and with notable shifts in this risk over a life span. For systemic lupus erythematosus (SLE) the female: male sex ratio is approximately 2.5:1 in prepubertal children, 10:1 during the reproductive years, falling to 2.5:1 again post-menopause. Associations have been observed between low testosterone levels and rheumatoid arthritis in male patients, and abnormalities of oestrogen metabolism in women with SLE. Patients with Klinefelter's syndrome also have a greater incidence of SLE and myasthenia gravis.

Direct evidence of the modulatory influence of sex hormones comes from animal models of SLE, Hashimoto's thyroiditis, and streptococcal cell wall induced autoimmune arthritis. Laboratory studies show that female animals are strikingly more susceptible to experimental models of autoimmunity. Diseased animals show improved survival when treated with antioestrogens such as tamoxifen, with antioestadiol antibodies or testosterone. However, supplementation with oestrogens accelerates and exacerbates disease.

SEX HORMONES AND IMMUNE RESPONSES

Immune diamorphism, the term given to differences in immune responses and regulation between the sexes, is apparent in the more notable humoral and cellular response present in women. Women exhibit stronger antibody responses to immunisation and infection and have higher levels of all antibody classes with the exception of IgE. Immune diamorphism is primarily a result of the immunomodulatory effects of sex hormones. Female and male sex hormones influence T cell populations, the production of specific antibodies, and proinflammatory mediators. In general female sex steroids enhance immune responses in both physiological and pathological states, whereas testosterone dampens inflammatory responses. Endogenous androgens appear to have stronger immunosuppressive effects than endogenous glucocorticoids.

Receptors for sex steroids have been identified on lymphocytes, monocytes, and mast cells. Androgen metabolism has been shown in alveolar macrophages with conversion of androstenedione into the more potent testosterone and dihydrotestosterone. Oestrogen and progesterone receptors have been found in significant numbers on mast cells isolated from the upper airways.

The in vitro effects of physiological concentrations of oestrogen and testosterone on the antigen non-specific differentiation of human peripheral blood monocytes (PBMC) have been examined. In cultures of PBMC from healthy individuals, oestrogen enhanced proliferation responses to pokeweed mitogen by 46%, whereas testosterone inhibited responses by 36% from baseline. Oestrogens increase B cell response, both in vitro and in vivo, while progesterone and androgens depress antibody production. The observation that the effects of sex steroids on lymphocyte maturation and proliferation are the same for both male and female cells studied in vitro suggests that these effects are not due to inherent genetic differences but rather to the hormonal milieu in which they are placed.

Oestrogen directly regulates the interferon γ gene and short exposure to physiological levels increases expression. Oestrogen is understood to have a biphasic dose-response, with higher levels promoting Th2 responses and lower levels a Th1 response. Progesterone has been shown to stimulate interleukin 4 production and promote the development of human Th2 cells.

IMPLICATIONS FOR THERAPY

These sex differences are of more than purely biological interest. The anti-inflammatory effects of testosterone and proinflammatory effects of female sex steroids at physiological levels greatly the prospect of utilizing this knowledge to therapeutic use, providing sex steroid effects on the reproductive system could be separated from their immunomodulating properties. Such possibilities should be an incentive for research into gender biodiversity. The strategies of drug development include modification of sex steroids, gender specific treatment, and organ specific therapy.

Androgens with anti-inflammatory properties but without the virilising effects form one avenue of enquiry. Further elucidation of the androgen signalling involved in modifying immune responses could result in novel therapies following the discovery of this pathway. In a similar fashion understanding female sex steroid actions, interactions, and signalling pathways could be used to develop agents which interfere with the process at a level that would not undermine their general activity elsewhere in the body. Such tissue specific treatment is already underway in the treatment of breast cancer with agents such as tamoxifen.

The virilising effects of androgens in females are an obvious concern and a limitation recognised at an early stage in autoimmune research. There are, however, adrenal androgens, such as dihydroepiandrosterone (DHEA), that are shared between males and females and that have fewer virilising effects. In a prospective open labelled uncontrolled study 50 female patients with mild to moderate SLE were treated with DHEA 50–200 mg/day. Levels of DHEA and testosterone increased, while disease activity by report and assessment using standardised instruments decreased. Significantly less prednisolone was used and improvements were sustained over the trial period of a year. Thirty four patients completed treatment for six months, and 21 for one year. Acneiform dermatitis, a recognised side effect of androgens, was the commonest reason for discontinuing therapy.

An alternative approach is gender tailored therapy. Male rheumatoid arthritis patients with low testosterone levels have been treated with testosterone. Restoring testosterone to normal levels was accomplished by an increase in the CD8 T cells with a lowering of the CD4/CD8 ratio and a decreased IgM rheumatoid factor. Significant increases in testosterone resulted in a clinically significant reduction in the number of affected joints and minimised the need for non-steroidal anti-inflammatory drugs. Males with Klinefelter's syndrome and with Sjogren's syndrome or SLE have clinical remission of their autoimmune disease and a reduction in associated inflammatory mediators and antibodies on being treated with replacement testosterone.

Another approach to reduction of systemic side effects is therapy targeted at the diseased organ, following the example of glucocorticoids with the emergence of inhaled and topical treatment.

REFERENCES


www.archdischild.com


Therapeutic implications of sex differences in asthma and atopy

M Osman

Arch Dis Child 2003 88: 587-590
doi: 10.1136/adc.88.7.587

Updated information and services can be found at:
http://adc.bmj.com/content/88/7/587

These include:

References
This article cites 46 articles, 16 of which you can access for free at:
http://adc.bmj.com/content/88/7/587#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Immunology (including allergy) (2018)
- Asthma (369)
- Reproductive medicine (945)
- Sexual health (352)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/